Filing Details
- Accession Number:
- 0001209191-17-058481
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-31 18:18:06
- Reporting Period:
- 2017-10-31
- Accepted Time:
- 2017-10-31 18:18:06
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1197032 | F Ian Smith | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2017-10-31 | 1,700 | $142.40 | 114,188 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-31 | 5,200 | $143.47 | 108,988 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-31 | 32,945 | $144.47 | 76,043 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-31 | 22,464 | $145.26 | 53,579 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-31 | 5,200 | $146.39 | 48,379 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-31 | 3,500 | $147.40 | 44,879 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-31 | 3,791 | $148.26 | 41,088 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-31 | 200 | $149.34 | 40,888 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 5,306 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $142.40 (range $141.83 to $142.75).
- Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $143.47 (range $142.91 to $143.85).
- Open market sales reported on this line occurred at a weighted average price of $144.47 (range $143.91 to $144.89).
- Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.93 to $145.87).
- Open market sales reported on this line occurred at a weighted average price of $146.39 (range $145.30 to $146.92).
- Open market sales reported on this line occurred at a weighted average price of $147.40 (range $146.93 to $147.90).
- Open market sales reported on this line occurred at a weighted average price of $148.26 (range $147.93 to $148.70).